http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022260939-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_661b3ea63e73acc96731eb73625b1bc2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e17617067c0e528e5fb48801ef1cd9e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa44f3b3705127611a67b54f764d6358 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4606b488b2da58aedcef4d84422dc5fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5709e51b5505ef043ed0887b167df5d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2111775ac549465d0622d16d571800c8 |
| publicationDate | 2022-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022260939-A2 |
| titleOfInvention | Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders |
| abstract | The present invention relates to agents which inhibit the expression and/or activity of transthyretin (TTR), e.g., a double stranded RNA (dsRNA) agent, or salt thereof, or an antisense oligonucleotide or a gene therapy targeting TTR, and the use of these agents in methods of treating or preventing Startgardt's disease, methods of decreasing Vitamin A levels or formation of toxic Vitamin A metabolites, and/or methods of halting progression of vision loss in a subject. The present invention also relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the retinal binding protein 4 (RBP4) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an RBP4 gene. The invention futher provides the use of RNAi agent targeting RBP4 and/or nucleic acid agents targeting TTR in methods of preventing and treating an RBP4-associated disorder, e.g., an ocular disease, e.g., Stargardt's disease, diabetic retinopathy, age-related macular degeneration (AMD), e.g., dry AMD and wet AMD; or a metabolic disorder, e.g., a disorder of glucose and lipid homeostasis, e.g., insulin resistance associated with type II diabetes, or a cardiovascular disease. |
| priorityDate | 2021-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1441.